ISC 2026 - Day 2

<h4>What if you could compress 179 days of grueling laboratory workflow into just 14 hours?</h4>In this episode of ‪ChromatographyTalk‬, ‪Organomation‬ General Manager David Oliva sits down with analytical chemist Laura Penabad to discuss her groundbreaking new research in biocatalysis and high-throughput screening. Evolving engineered enzymes typically requires checking thousands of variants—a massive bottleneck when traditional Liquid Chromatography-Mass Spectrometry (LC-MS) runs take minutes per sample. Laura reveals how her team built a modular screening platform that shatters this limitation, running samples 128 times faster than standard methods without sacrificing analytical accuracy.Laura breaks down the "orchestra" of technologies making this possible, including coupling nanoliter droplet microfluidics with Cyclic Ion Mobility-Mass Spectrometry (cIM-MS) to separate complex chemical isomers in milliseconds. She also shares the chaotic but triumphant behind-the-scenes stories of her PhD journey—from presenting a "comically bad" early poster at ASMS to recruiting an undergraduate mechanical engineer to build custom automation software from scratch.If you are an early-career researcher, a mass spec enthusiast, or curious about the future of synthetic biology and machine learning in chemistry, this episode is packed with invaluable intuition and advice.<h3>Video Transcription</h3><h4>From Months to Hours: Droplet Ion Mobility–MS for Biocatalysis Screening</h4>High-throughput screening is central to directed enzyme evolution, but conventional analytical workflows can create a difficult compromise: extremely fast screens often provide limited structural information, while techniques such as LC-MS offer much richer chemical insight at the cost of throughput. In a recent interview, analytical chemist Laura described how her work with droplet-based cyclic ion mobility mass spectrometry is helping bridge that gap—providing rapid analysis while retaining the ability to distinguish structurally similar products.Her research grew from an initially modest proof of concept into a screening platform capable of analyzing a 96-well plate in roughly ten minutes. The resulting workflow was approximately 128 times faster than a conventional three-minute LC-MS analysis, opening new possibilities for directed evolution campaigns in which thousands of enzyme variants need to be evaluated.<h4>Directed evolution needs better analytical screening</h4>Biocatalysis takes advantage of enzymes as highly selective catalysts capable of performing reactions under relatively mild conditions. Directed evolution extends those capabilities by deliberately modifying enzyme sequences, expressing large numbers of variants, screening their activity, and using the best-performing mutants as starting points for subsequent rounds of evolution.The process can be repeated multiple times, progressively steering an enzyme toward improved activity, altered substrate specificity, or even chemistry that does not occur naturally.But the effectiveness of directed evolution depends heavily on the screening step. The more variants that can be analyzed—and the more useful chemical information that can be collected for each one—the more effectively researchers can explore the enormous sequence space available to an enzyme.For Laura, this created a clear analytical challenge: develop a screening platform that was substantially faster than conventional chromatographic analysis without sacrificing the structural discrimination needed for chemically similar products.<h4>From an imperfect first experiment to a working platform</h4>The project did not begin with a polished high-throughput workflow.Laura recalled looking back at her 2023 ASMS poster, where the early system was still working with standards rather than true isomeric samples. Droplet introduction was slow—around six seconds per droplet—and the signals were far from the ideal reproducible, square, flat-topped profiles expected from replicate droplets.Nevertheless, simply producing a droplet signal represented an important first milestone.The decisive change came when the project stopped being treated merely as a demonstration that droplet ion mobility–MS could work and instead became a deliberate effort to build a robust screening platform.Laura approached the problem in modules. First came reliable droplet introduction. Then the ion mobility separation method. Quantification became another independent component. Matrix effects were introduced later, gradually making the system resemble the conditions expected with real screening samples.Each layer was tested before another was added.This stepwise strategy became one of the central principles of the project: rather than attempting to optimize the entire system simultaneously, individual components were developed, challenged, and then assembled into an increasingly realistic workflow.<h4>Finding the middle ground between speed and structural information</h4>One of the biggest analytical problems in high-throughput screening is distinguishing products with the same nominal or exact mass.Constitutional isomers may contain the same atoms and therefore generate the same mass-to-charge ratio, while differing only in how functional groups are arranged within the molecular structure. Very rapid optical or mass-based screens may therefore struggle to distinguish them.Traditional LC-MS can solve many of these problems through chromatographic separation, but a several-minute analysis rapidly becomes impractical when thousands of enzyme variants must be screened.Ion mobility offered Laura’s team another option.Rather than separating compounds on a chromatographic timescale, ion mobility can differentiate ions according to their gas-phase behavior on a much shorter timescale. In the workflow described in the interview, this created a useful compromise: not the kilohertz throughput possible with some simple screening technologies, but dramatically faster structural differentiation than conventional LC-MS.The goal was therefore not simply to achieve the fastest possible screen, but to find a middle-throughput analytical regime with enough resolving power to answer chemically meaningful questions.<h4>A 96-well plate in about ten minutes</h4>That strategy eventually produced one of the most striking results of the project.The droplet cyclic ion mobility–MS platform processed a 96-well plate in roughly ten minutes, while maintaining quantitative results comparable with the conventional LC-MS workflow used for comparison. According to the interview, this represented an approximately 128-fold increase in analysis speed relative to a three-minute LC-MS run.Laura described the successful plate experiment less as a surprise than as confirmation that the modular development strategy had worked.Before reaching that point, the workflow had already been challenged through a sequence of increasingly demanding experiments: droplet formation, ion mobility separation, calibration, matrix-containing calibration, and cross-testing analytes at different concentrations. By the time the complete plate was analyzed, each individual part of the analytical system had already been tested under progressively more realistic conditions.<h4>What does that speed mean for directed evolution?</h4>The impact becomes even clearer when the workflow is considered at the scale of an entire directed-evolution campaign.Laura’s manuscript estimated that a five-round campaign involving 5,000 variants would require approximately 179 days using the conventional LC-MS workflow but only about 14 hours using the new platform.Compressing months of analytical work into less than a day has consequences beyond laboratory productivity.It allows researchers to screen more enzyme variants and therefore sample a larger portion of sequence space. But the resulting datasets may also become increasingly valuable for computational approaches.Rather than retaining information only about the best-performing enzyme variant, researchers can preserve data describing variants that performed poorly as well as those that succeeded. When genotype and phenotype information remain linked through the well-plate workflow, these larger datasets can potentially provide richer input for machine-learning models designed to guide subsequent rounds of enzyme evolution.Faster analysis therefore does more than accelerate an existing experiment—it can change the scale and design of the experiment itself.<h4>Balancing ion mobility resolution and signal</h4>Increasing cyclic ion mobility separation time can improve resolution, but it also introduces an important trade-off: additional passes can reduce signal.Laura optimized this balance experimentally by continuously infusing mixtures containing both isomers and progressively adjusting the ion mobility conditions. After tuning parameters such as wave height and velocity, increasing the separation to three passes provided baseline resolution at the high analyte concentrations used during method development.<blockquote>Concentration, however, also mattered.</blockquote>At higher ion populations, space-charge effects could broaden peaks and reduce the baseline separation. This meant that the optimal number of passes could not be selected independently of the concentration range required by the final assay.Her broader advice for optimization is therefore application-driven: decide first what the analytical method actually needs to accomplish.More speed will almost always require sacrificing something—resolution, signal intensity, quantitative precision, or another performance parameter. The key is to identify which compromise the application can tolerate and then optimize the system around that requirement.<h4>Solving droplet carryover with a practical compromise</h4>Droplet-based workflows present their own engineering challenges, including carryover between neighboring samples.In Laura’s system, analytes showed little tendency to partition into the fluorinated oil separating aqueous droplets within the Teflon tubing. The more troublesome carryover occurred closer to electrospray ionization, where a small amount of sample could remain associated with the interface and appear when the next droplet arrived.Rather than adding excessive engineering complexity to an already elaborate platform, the researchers adopted a pragmatic solution: a sacrificial wash droplet between analytical samples.It is an example of a recurring theme throughout the project. The objective was not to construct the theoretically most sophisticated droplet system, but to create a screening workflow that remained sufficiently robust, reproducible, and practical for large numbers of samples.<h4>High-throughput analysis also requires high-throughput data processing</h4>Accelerating the mass spectrometry experiment created another bottleneck: the data.The instrument produced a continuous intensity-versus-time trace rather than a neatly organized well-plate dataset. With small experiments, Laura could manually identify individual droplets and process the results in spreadsheets. That approach quickly became unrealistic as sample numbers increased.The solution emerged through collaboration with an undergraduate mentee, Aiden, who helped develop a dedicated software tool for processing the continuous traces.Laura defined how the software should behave and how the analytical information should be organized, while Aiden developed the computational implementation. The workflow itself was subsequently adjusted to make automated data processing more reliable—for example, by introducing marker columns that allowed the software to recognize the end of each plate row.The resulting tool can accept the acquired traces together with information about plate dimensions and replicates and automatically return parameters including peak identity, duration, and the corresponding well position. A later version also generated an automatically populated heat map.The experience illustrates how improving analytical throughput often requires simultaneous development of instrumentation, experimental design, and informatics. Making the measurement faster is useful only if the resulting data can be processed at a comparable speed.<h4>Mentoring became part of the scientific process</h4>The software project also reflects another theme Laura emphasized throughout the interview: the value of mentoring.Several younger researchers contributed directly to the development of the final platform. Laura described mentees not simply as additional hands in the laboratory but as scientists capable of proposing their own hypotheses and experimental ideas.Working with undergraduate researchers also influenced the way she organized experiments.Because their available laboratory time was limited, each task needed to have a clear purpose. That encouraged a more disciplined approach to experimental planning: instead of performing experiments simply because they could be done, the team had to ask which experiment would most efficiently answer the next important question.In that sense, mentoring became another mechanism for improving the research itself.<h4>The next step: continuous, automated screening</h4>Despite the dramatic increase in analytical speed, the current workflow still includes manual operations such as loading tubing and connecting the sample stream to the mass spectrometer.The next engineering challenge is therefore automation.Laura described ongoing work using the Venturi effect to pull samples directly from wells into the droplet system. Building on previous work in the laboratory with 96-well plates, she has already tested this approach with as many as 2,000 samples.The long-term direction is clear: continuous and robust droplet generation, automated handling of thousands of samples, rapid ion mobility separation, mass spectrometric detection, and automated reconstruction of the resulting data into plate-based outputs.Combining those elements could move the system closer to the type of large-scale screening required for increasingly ambitious biocatalysis campaigns.<h4>Learning mass spectrometry one problem at a time</h4>Laura also reflected on the broader experience of developing the platform during her PhD.Ion mobility and mass spectrometry initially appeared intimidating, particularly because they combine concepts from analytical chemistry, physical chemistry, separations, instrumentation, and electrical engineering. What eventually changed was not simply learning more facts, but developing the ability to move repeatedly between theory and experiment.An unexpected result sends the researcher back to the underlying theory. A better understanding suggests a modified experiment. That experiment creates another observation, gradually building intuition about how the system behaves.Her advice to early-career scientists is therefore to accept that this process takes time.Advanced analytical techniques may initially appear overwhelming, but understanding develops incrementally through repeated interaction between theory, experimentation, failure, and refinement. Equally important, she emphasized the role of the supportive ion mobility–mass spectrometry community in making a technically demanding field more approachable for young researchers.From the first inconsistent droplets to a platform capable of processing thousands of samples, that iterative mindset ultimately shaped the entire project.<blockquote>This text has been automatically transcribed from a video presentation using AI technology. It may contain inaccuracies and is not guaranteed to be 100% correct.</blockquote><blockquote><h4>Concentrating on Chromatography Podcast</h4>Dive into the frontiers of chromatography, mass spectrometry, and sample preparation with host David Oliva. Each episode features candid conversations with leading researchers, industry innovators, and passionate scientists who are shaping the future of analytical chemistry. From decoding PFAS detection challenges to exploring the latest in AI-assisted liquid chromatography, this show uncovers practical workflows, sustainability breakthroughs, and the real-world impact of separation science. Whether you’re a chromatographer, lab professional, or researcher you'll discover inspiring content!You can find Concentrating on Chromatography Podcast in podcast apps:<ul><li><a target="_blank" rel="noopener noreferrer" href="https://open.spotify.com/show/1wZg67rCjoGju4yhqxI3tL">Spotify</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podcasts.apple.com/tz/podcast/concentrating-on-chromatography/id1788429185">Apple podcast</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://podscan.fm/podcasts/concentrating-on-chromatography">podscan</a></li></ul>and on <a target="_blank" rel="noopener noreferrer" href="https://www.youtube.com/@ChromatographyTalk/videos">YouTube channel</a></blockquote>

Droplet Cyclic Ion Mobility Mass Spec: Compressing Months of Enzyme Screening Into Just 14 Hours

ISC 2026 - Day 3

Article

Events

Video

Scientists

Interview

The International Symposium on Chromatography (ISC) represents the oldest conference series focussing on separation science. ISC symposia have been organised since 1956 in each even year. ISC is internationally recognised as one of the premier meeting series for discussion of all modes of chromatography and separation science with a broad coverage of techniques and applications.

International Symposium on Chromatography - (ISC)

Organomation, founded in 1959, designs and manufactures high-quality nitrogen evaporators and extraction systems. Known for innovation and durability, their lab instruments are used globally for efficient sample preparation with strong customer support.

Organomation

CJC No DAC – MOD GRF (1-29)/Ipamorelin Blend Analysis

HPLC analysis of a CJC No DAC – MOD GRF (1-29) and ipamorelin blend for identification and separate quantification of both peptides in mg per vial.

This analysis is designed to confirm the identity and separately determine the amount of CJC No DAC – MOD GRF (1-29) and ipamorelin in a combined lyophilized sample. HPLC testing measures both target peptides, with results reported in mg per vial.Peptide purity cannot be reliably determined in blends because impurities originating from the individual peptides may overlap in the chromatographic data and cannot be clearly attributed to a specific component.<h4>CJC No DAC – MOD GRF (1-29) and Ipamorelin</h4>CJC No DAC, also known as MOD GRF (1-29), and ipamorelin are two separate peptides that may be combined in a single product. This analysis is specifically intended for blends containing both target compounds.The final report confirms the identity of both peptides and states the amounts of CJC No DAC – MOD GRF (1-29) and ipamorelin separately.<h4>What the Analysis Determines</h4><ul><li>Identity of CJC No DAC – MOD GRF (1-29)</li><li>Identity of ipamorelin</li><li>Amount of CJC No DAC – MOD GRF (1-29) in the sample</li><li>Amount of ipamorelin in the sample</li><li>Results in mg per vial for each target peptide</li></ul><h4>Analysis Parameters</h4><ul><li>Target compounds: CJC No DAC – MOD GRF (1-29) and ipamorelin</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format: mg per vial for each target peptide</li><li>Minimum sample amount: one whole unopened vial containing the lyophilizate</li><li>Average turnaround time: 7 business days</li><li>Peptide purity: not measured</li></ul><blockquote><h5>Important Notice</h5>Peptide purity cannot be determined for a CJC No DAC – MOD GRF (1-29) and ipamorelin blend. Impurities associated with both peptides may overlap in the chromatographic data and cannot be reliably assigned to the individual target compounds.The final report provides identification and separately measured amounts of both peptides. Peptide purity is not included in the results.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

CJC-1295 DAC Analysis

HPLC analysis of CJC-1295 DAC for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of CJC-1295 DAC in lyophilized samples and raw API powders. HPLC testing provides information about the actual content of the target peptide and its purity relative to chromatographically detectable impurities.<h4>CJC-1295 DAC</h4>CJC-1295 DAC is a synthetic peptide composed of 29 amino acid residues. Its structure contains D-alanine and an amidated C-terminus. The stated molecular weight is approximately 3,368 Da.HPLC analysis confirms the presence of CJC-1295 DAC in the sample, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of CJC-1295 DAC</li><li>Amount of CJC-1295 DAC in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: CJC-1295 DAC</li><li>CAS number: 446262-90-4</li><li>Molecular weight: 3,368 Da</li><li>Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of CJC-1295 DAC in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

CJC-1295 No DAC – MOD GRF (1-29) Analysis

HPLC analysis of CJC-1295 no DAC – MOD GRF (1-29) for identity confirmation, amount determination and peptide purity in lyophilized samples and API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of CJC-1295 no DAC, also known as MOD GRF (1-29), in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content and its purity relative to chromatographically detectable impurities.<h4>CJC-1295 No DAC – MOD GRF (1-29)</h4>CJC-1295 no DAC is a synthetic peptide composed of 29 amino acid residues. It is also known as CJC-1295 without DAC or Modified GRF 1-29.Unlike CJC-1295 DAC, this peptide does not contain a Drug Affinity Complex modification. Its structure includes D-alanine and an amidated C-terminus.HPLC analysis confirms the presence of CJC-1295 no DAC in the sample, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of CJC-1295 no DAC – MOD GRF (1-29)</li><li>Amount of CJC-1295 no DAC in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: CJC-1295 no DAC</li><li>Other names: CJC-1295 without DAC, Modified GRF 1-29, MOD GRF (1-29)</li><li>Molecular weight: 3,670 Da</li><li>Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of CJC-1295 no DAC in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Cortagen Analysis

HPLC analysis of Cortagen for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of Cortagen in lyophilized samples and raw API powders. HPLC testing provides information about the actual content of the target peptide and its purity relative to chromatographically detectable impurities.<h4>Cortagen</h4>Cortagen is a short synthetic peptide composed of four amino acid residues and is therefore classified as a tetrapeptide. Its sequence is Ala-Glu-Asp-Pro, and its molecular weight is approximately 430 Da.HPLC analysis confirms whether the sample contains Cortagen, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of Cortagen</li><li>Amount of Cortagen in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Cortagen</li><li>Molecular weight: 430 Da</li><li>Sequence: Ala-Glu-Asp-Pro</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of Cortagen in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Crystagen Analysis

HPLC analysis of Crystagen for identity confirmation, amount determination and peptide purity in lyophilized samples and raw API powders.

This analysis is designed to confirm the identity and determine the amount and peptide purity of Crystagen in lyophilized samples and raw API powders. HPLC testing provides information about the target peptide content and its purity relative to chromatographically detectable impurities.<h4>Crystagen</h4>Crystagen is a short synthetic peptide composed of three amino acid residues and is therefore classified as a tripeptide. Its Glu-Asp-Pro sequence consists of glutamic acid, aspartic acid and proline.The molecular weight of Crystagen is approximately 359 Da. HPLC analysis confirms the presence of Crystagen in the sample, determines its amount and evaluates peptide purity.<h4>What the Analysis Determines</h4><ul><li>Identity of Crystagen</li><li>Amount of Crystagen in the sample</li><li>Peptide purity</li><li>Results in a format appropriate for the submitted sample type</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Crystagen</li><li>Molecular weight: 359 Da</li><li>Sequence: Glu-Asp-Pro-OH</li><li>Testing method: HPLC</li><li>Detection limit: less than one twentieth of the usual dosage per vial</li><li>Result format for lyophilizates: mg per vial and peptide purity</li><li>Alternative result format: m/m purity and peptide purity</li><li>Minimum lyophilizate sample: one whole unopened vial containing the lyophilizate</li><li>Minimum raw API powder sample: 30 mg in a sealed glass vial to prevent moisture absorption</li><li>Average turnaround time: 7 business days</li></ul><blockquote><h5>Important Notice</h5>The alternative m/m purity result format is intended exclusively for raw API powders. For lyophilized samples, the standard result format provides the amount of Crystagen in mg per vial together with peptide purity.</blockquote><h4>Additional Analyses</h4><h5>TFA Analysis</h5><ul><li>Detection and measurement of trifluoroacetic acid (TFA) in the sample. Results are reported in mg per vial.</li></ul><h5>Raw Data</h5><ul><li>Delivery of the available raw analytical data from the primary test and all applicable additional analyses.</li></ul><h5>Fentanyl Presence Analysis</h5><h5>Alternative Result Format – m/m Purity</h5><ul><li>Alternative reporting of the result as mass-by-mass purity. This option is intended exclusively for raw API powders.</li></ul><h5>Variance Testing</h5><ul><li>Analysis of multiple sample units to assess variation within a single batch. All submitted samples must originate from the same batch of the same product.</li></ul><h5>pH Measurement</h5><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2522">Endotoxin Analysis</a></h5><ul><li>Measurement of bacterial endotoxins, particularly lipopolysaccharides (LPS), in the sample. This analysis is available only for finished products and should not be ordered for raw powders.</li><li>The standard test provides accurate results up to 10 EU per vial. Values above 10 EU per vial are estimated and require an additional test with a different dilution for precise determination. Sending two vials is therefore recommended.</li><li>Where endotoxin levels above 10 EU per vial are expected, the method can be calibrated for the higher range in advance.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2526">CHNS Mass Report</a></h5><ul><li>Elemental analysis providing accurate measurement of nitrogen and sulphur content. The results can be used to determine Net Peptide Content (NPC).</li></ul><h5>Additional Report</h5><ul><li>A separate additional laboratory report issued under a different client name.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">LC-MS Screening for Peptide Contamination</a></h5><ul><li>LC-MS screening for contamination with other peptides or peptide degradation products. Detection is limited to peptides included in the available testing portfolio.</li><li>The initial screening provides identification only. If contamination is detected, quantitative measurement may subsequently be ordered.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2527">Sterility Testing</a></h5><ul><li>TAMC and TYMC testing checks the product for the presence of bacteria, yeasts and moulds. Additional unopened sample units must be submitted for analysis. The average turnaround time for this test is 14 days.</li></ul><h5><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis</a></h5><ul><li>Detection of arsenic, cadmium, lead and mercury in the sample. Testing for other metals can be arranged individually.</li></ul>

Avanafil analysis

Targeted HPLC analysis of avanafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Avanafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of avanafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Avanafil</h4>Avanafil, marketed under names such as Stendra and Spedra, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It works by inhibiting PDE5 and thereby supporting the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.Avanafil is clinically used for the treatment of erectile dysfunction. It belongs to the same pharmacological class as sildenafil, tadalafil, and vardenafil, but has its own pharmacokinetic and selectivity profile.<h4>Key Features</h4><ul><li>Targeted identification and quantification of avanafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Avanafil</li><li>Other names: Stendra, Spedra</li><li>CAS number: 330784-47-9</li><li>Testing method: HPLC</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for avanafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Dapoxetine analysis

Targeted HPLC analysis of dapoxetine in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Dapoxetine Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of dapoxetine in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Dapoxetine</h4>Dapoxetine is a short-acting selective serotonin reuptake inhibitor (SSRI) developed for on-demand use. It increases serotonin activity in the central nervous system and is used in some countries for the treatment of premature ejaculation.Dapoxetine is marketed under names such as Priligy and EJ-30. Its pharmacological profile differs from longer-acting SSRIs commonly used in the treatment of depression and anxiety disorders.<h4>Key Features</h4><ul><li>Targeted identification and quantification of dapoxetine</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Dapoxetine</li><li>Other names: EJ-30, Priligy</li><li>CAS number: 119356-77-3</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for dapoxetine. It does not automatically screen the sample for other SSRIs, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of dapoxetine required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Sildenafil analysis

Targeted HPLC analysis of sildenafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Sildenafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of sildenafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Sildenafil&nbsp;</h4>Sildenafil, widely known under the trade name Viagra, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and enhances the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.Sildenafil is clinically used primarily for the treatment of erectile dysfunction and is also used in specific formulations for pulmonary arterial hypertension.<h4>Key Features</h4><ul><li>Targeted identification and quantification of sildenafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Sildenafil</li><li>Other name: Viagra</li><li>CAS number: 139755-83-2</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for sildenafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of sildenafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Tadalafil Analysis

Targeted HPLC analysis of tadalafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Tadalafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of tadalafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Tadalafil</h4>Tadalafil, widely known under the trade name Cialis, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and supports the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.Tadalafil is clinically used primarily for the treatment of erectile dysfunction and is also used for conditions such as benign prostatic hyperplasia and pulmonary arterial hypertension.<h4>Key Features</h4><ul><li>Targeted identification and quantification of tadalafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Tadalafil</li><li>Other name: Cialis</li><li>CAS number: 171596-29-5</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for tadalafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of tadalafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GCMS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Vardenafil analysis

Targeted HPLC analysis of vardenafil in pills, tablets, capsules, and raw API powders. The test confirms compound identity and determines its content.

The Vardenafil Analysis is a targeted laboratory test designed to confirm the identity and determine the amount of vardenafil in oral dosage forms and raw active pharmaceutical ingredient (API) powders.The analysis is suitable for pills, tablets, and capsules, with results reported in milligrams per tablet or capsule. Raw API powders can be evaluated by percentage content, with optional purity reporting in % (m/m).<h4>About Vardenafil</h4>Vardenafil, marketed under names such as Levitra, Staxyn, and Vivanza, is an orally active phosphodiesterase type 5 (PDE5) inhibitor. It inhibits PDE5 and supports the nitric oxide–cGMP signalling pathway involved in smooth muscle relaxation and increased blood flow.Vardenafil is clinically used for the treatment of erectile dysfunction. It belongs to the same pharmacological class as <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2519">sildenafil</a>, <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2520">tadalafil</a>, and <a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2517">avanafil</a>.<h4>Key Features</h4><ul><li>Targeted identification and quantification of vardenafil</li><li>Suitable for pills, tablets, capsules, and raw API powders</li><li>Analysis by HPLC</li><li>Results for oral products reported in mg per tablet or capsule</li><li>Results for raw API powders reported as percentage content</li><li>Optional purity reporting in % (m/m) for raw API powders</li><li>Minimum sample amount of three tablets or capsules</li><li>Minimum sample amount of 200 mg for raw API powders</li><li>Average turnaround time of 7 business days</li></ul><h4>Analysis Parameters</h4><ul><li>Target compound: Vardenafil</li><li>Other names: Levitra, Staxyn, Vivanza</li><li>CAS number: 224785-90-4</li><li>Testing method: HPLC</li><li>Minimum amount of target compound for evaluation in oral products: 2 mg per pill, tablet, or capsule</li><li>Minimum content of target compound for evaluation in raw API powders: 10%</li><li>Result format for oral products: mg per tablet or capsule</li><li>Result format for raw API powders: % [98%+, 96%+ or % value such as 94.15%]</li><li>Minimum sample amount for oral products: Three tablets or capsules</li><li>Minimum sample amount for raw API powders: 200 mg</li><li>Average turnaround time: 7 business days</li></ul><blockquote>Important Notice<ul><li>This analysis is specifically intended for vardenafil. It does not automatically screen the sample for other PDE5 inhibitors, related compounds, contaminants, or undeclared substances.</li><li>For oral products, the minimum amount of vardenafil required for evaluation is 2 mg per pill, tablet, or capsule. For raw API powders, the minimum content is 10%. Samples below these values may not be reliably evaluated within the standard scope of the analysis.</li><li>Purity reporting in % (m/m) is available only for raw API powders.</li></ul></blockquote><h4>Optional Additional Analyses</h4>The following optional laboratory services are available:<ul><li>Complete Raw Analytical Data</li><li>Alternative Result Format: Purity in % (m/m) – only for raw API powders</li><li>Batch Variance Testing</li><li>Fentanyl Screening</li><li><a target="_blank" rel="noopener noreferrer" href="https://lcms.labrulez.com/products/2524">GC–MS Contamination Screening</a></li><li><a target="_blank" rel="noopener noreferrer" href="https://icpms.labrulez.com/products/2525">Heavy Metals Analysis (As, Cd, Pb, Hg)</a></li><li>Additional Laboratory Report</li></ul>

Related content

ISC 2026 - Day 3

Droplet Cyclic Ion Mobility Mass Spec: Compressing Months of Enzyme Screening Into Just 14 Hours

ISC 2026 - Day 2